A Phase 1b/2 Study of BGB-16673 in Combination With Other Anti-Cancer Drugs in People With B-Cell Cancer

Full Title

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination with Other Agents in Patients with Relapsed or Refractory B-cell Malignancies

Purpose

Researchers are assessing treatment with BGB-16673 in combination with other anti-cancer medications in people with B-cell cancers. These cancers include:

• Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma
• Follicular lymphoma
• Richter’s transformation
• Waldenstrom macroglobulinemia
• Marginal zone lymphoma
• Mantle cell lymphoma

The people in this study have cancer that came back or keeps growing after treatment.

BGB-16673 degrades a protein called BTK. BTK plays a role in the survival of CLL cells. If you join this study, you will get BGB-16673 plus one of these drugs, depending on the study group that you participate in:

• Sonrotoclax. This drug inhibits a protein called Bcl-2. Bcl-2 stops cancer cells from dying.
• Zanubrutinib. This drug is a BTK inhibitor.
• Mosunetuzumab. This bispecific antibody helps the immune system fight cancer by directing T cells to kill cancerous B cells.

BGB-16673, sonrotoclax, and zanubrutinib are each taken orally (by mouth). Mosunetuzumab is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

• Have a B-cell cancer that came back or keeps growing after treatment.
• Have recovered from the serious side effects of previous therapies before getting the study treatment.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Meghan Thompson’s office at 646-608-4253.